Metabolic
Tirzepatide
Dual GIP/GLP-1 receptor agonist reference standard for in-vitro incretin-pathway studies.
Indexed literature
Original citations from PubMed and ClinicalTrials.gov matched to Tirzepatide. Indexing is not a quality endorsement; registration is not a published result.
- ClinicalTrials.govRegistered trial — no results postedReal-World Outcomes of Tirzepatide in Pakistani Adults With Obesity, Prediabetes, and Type 2 Diabetes
Updated 2026-10-20 · NOT YET RECRUITING
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
- PubMedResearch publicationTirzepatide-Associated Lithium Toxicity: A Case Report.
Journal of clinical psychopharmacology · 2026 Oct 19
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationReal-world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide.
Diabetic medicine : a journal of the British Diabetic Association · 2026 Oct 19
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- ClinicalTrials.govRegistered trial — no results postedA Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Updated 2026-10-19 · COMPLETED PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
- ClinicalTrials.govRegistered trial — no results postedA Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Updated 2026-10-19 · COMPLETED PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
- ClinicalTrials.govRegistered trial — no results postedA Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
Updated 2026-10-19 · NOT YET RECRUITING PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
- ClinicalTrials.govRegistered trial — no results postedA Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Updated 2026-10-19 · NOT YET RECRUITING PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
- PubMedResearch publicationGLP-1 receptor agonist therapy and incident atrial fibrillation in non-diabetic adults with obesity and chronic kidney disease: a propensity matched cohort study.
International journal of cardiology · 2026 Oct 17
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationEconomic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran.
Journal of diabetes and metabolic disorders · 2026 Dec
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationGlucagon-Like Peptide-1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity.
Journal of the American Heart Association · 2026 Oct 16
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationRecurrent In-Stent Restenosis and Accelerated Neoatherosclerosis in a Middle-Aged Woman With High Inflammatory Burden.
JACC. Case reports · 2026 Oct 16
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationIncretin Therapy Before Metabolic and Bariatric Surgery: Cardiorenal Protection or Physiological Preconditioning?
The American journal of medicine · 2026 Oct 16
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationReal-world, digital-first delivery of GLP-1 receptor agonist therapy in women.
Nature medicine · 2026 Oct 16
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- ClinicalTrials.govRegistered trial — no results postedGLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation
Updated 2026-10-16 · WITHDRAWN
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
- PubMedResearch publicationOutcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis.
European journal of preventive cardiology · 2026 Oct 15
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationClinical Feasibility of a Low-Dose Tirzepatide Strategy in Older Adults with Type 2 Diabetes: Persistence, Metabolic Benefit, and Treatment Simplification in a Real-World Cohort.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026 Oct 15
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationA Retrospective Chart Review of Tirzepatide and Semaglutide Use in Prediabetes Management and Cardiometabolic Outcomes in a Rural Primary Care Setting.
Journal of doctoral nursing practice · 2026 Oct 15
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- ClinicalTrials.govRegistered trial — no results postedAssessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1
Updated 2026-10-15 · NOT YET RECRUITING NA
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
- ClinicalTrials.govRegistered trial — no results postedA Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
Updated 2026-10-15 · RECRUITING PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
- ClinicalTrials.govRegistered trial — no results postedEffects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients
Updated 2026-10-15 · NOT YET RECRUITING
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
- PubMedReviewPharmacotherapy for MASLD/MASH: approved therapies, drug repurposing, and emerging mechanism-based candidates.
Expert opinion on pharmacotherapy · 2026 Oct 14
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedReviewGLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?
Acta diabetologica · 2026 Oct 14
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationReal-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity.
Diabetes, obesity & metabolism · 2026 Oct 14
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationEffects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis.
The Journal of clinical endocrinology and metabolism · 2026 Oct 13
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
Materials supplied by Basic Tides are for in-vitro laboratory research only. This page contains no protocols, no dosing information and no therapeutic framing; third-party literature is indexed for reference and is not authored, endorsed or interpreted by Basic Tides.